Loading
Top

News

Scroll Down

Taking a novel approach to drug development

News

Lantern Pharma is proud to be featured in multitude of media outlets. Our goal is to crush cancer by leveraging A.I. and machine learning. By sharing our message and news, we hope to foster additional collaborations and partnerships, and engage with the clinical community in developing the right treatments for the right patients.

How Technologies Like AI and Machine Learning Can Help With the Development of Medicine

TradeTalks Video Broadcasts - With Jill Malandrino

September 22, 2021
Read Now
Read Now
Download Now

Join our team and help transform the cancer drug development process, cost and timeline!

August 26, 2021
Read Now
Read Now
Download Now

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

August 16, 2021
Read Now
Read Now
Download Now

Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO

August 3, 2021
Read Now
Read Now
Download Now

How AI Is Expediting Medicine Development

July 28, 2021
Read Now
Read Now
Download Now

Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

July 26, 2021
Read Now
Read Now
Download Now

Preclinical Data on New Pancreatic Cancer Drug Shines with over 90% Efficacy

July 20, 2021
Read Now
Read Now
Download Now

Midday Hot Stocks: SPCE falls as Bezos flies; HAL, UBS rise on earnings; LTRN gets strong pre-clinical data

July 20, 2021
Read Now
Read Now
Download Now

How AI Is Transforming the Healthcare Landscape & Accelerating the Development of Medicine

July 9, 2021
Read Now
Read Now
Download Now

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

May 3, 2021
Read Now
Read Now
Download Now

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing

April 29, 2021
Read Now
Read Now
Download Now

New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

April 13, 2021
Read Now
Read Now
Download Now

Lantern ($LTRN) Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with

March 17, 2021
Read Now
Read Now
Download Now

A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications

March 4, 2021
Read Now
Read Now
Download Now

Technology Is Rapidly Changing Cancer Care

January 23, 2021
Read Now
Read Now
Download Now

AI offers promise but faces barriers in drug development

December 10, 2020
Read Now
Read Now
Download Now

Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development

November 18, 2020
Read Now
Read Now
Download Now

Episode 68: Rocking Garage Biotech

October 29, 2020
Read Now
Read Now
Download Now

What going public means for Lantern Pharma

September 29, 2020
Read Now
Read Now
Download Now

Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature

September 23, 2020
Read Now
Read Now
Download Now